Stock itci.

May 2, 2023 · ITCI 4.98%. 58. See ITCI Report. Overall market sentiment has been high on Intra-Cellular Therapies Inc ( ITCI) stock lately. ITCI receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Intra-Cellular Therapies Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ITCI! Nov 7, 2023 · The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ... Mar 6, 2023 · Read why ITCI stock is a Hold. Intra-Cellular Therapeutics develops small molecule drugs targeting the CNS for neuropsychiatric and neurological disorders. Read why ITCI stock is a Hold. Nov 22, 2023 · The latest Intra-Cellular Therapies stock prices, stock quotes, news, and ITCI history to help you invest and trade smarter. Nov 7, 2023 · The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

The average price recommended by analysts for Intra-Cellular Therapies Inc (ITCI) is $77.54, which is $16.26 above the current market price. The public float for ITCI is 93.65M and currently, short sellers hold a 3.65% of that float. On December 01, 2023, ITCI’s average trading volume was 845.52K shares. Top 5 EV Tech Stocks to Buy for 2023.A high-level overview of Intra-Cellular Therapies, Inc. (ITCI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

1.05%. ¥6.6T. VST Industries Ltd. 0.49%. ₹52.52B. ITC | Complete ITC Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report. ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report. Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report.

Aug 12, 2023 · According to Seeking Alpha data: ITCI capital structure reveals a market cap of $5.59B with minimal debt and a healthy cash reserve, resulting in an enterprise value of $5.10B. Intra-Cellular Therapies ( NASDAQ: ITCI) stock traded much higher recently after it had obtained FDA approval for its drug CAPLYTA (lumateperone) for the treatment of adults with bipolar ...April 27, 2023 at 10:03 AM · 5 min read. Wall Street expects a year-over-year increase in earnings on higher revenues when Intra-Cellular Therapies (ITCI) reports results for the quarter ended ...ITCI Stock Overview. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

Intra-Cellular Therapies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ITCI updated stock price target summary.

Press Releases. Year. November 15, 2023. Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference. PDF Version. November 2, 2023. Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance. PDF Version. October 31, 2023.

See the latest Intra-Cellular Therapies Inc stock price (NASDAQ:ITCI), related news, valuation, dividends and more to help you make your investing decisions.Intra-Cellular Therapies (ITCI) Stock Forecast, Price Targets ... The stock of Intra-Cellular Therapies Inc (ITCI) has gone up by 5.10% for the week, with a -1.20% drop in the past month and a -13.62% drop in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are 3.88% for ITCI. The simple moving average for the last 20 days is -0.20% for ITCI stock ...ITCI The Nasdaq Global Select Market ... Common stock, $ 0.0001 par value: 175,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, ...Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) reported Q3 2023 total revenues of $126.2 million, a 75% increase compared to the same period in 2022. CAPLYTA Q3 2023 net product sales were $125.8 million, representing a 75% increase. CAPLYTA total prescriptions increased 71% in Q3 2023. The company raised its 2023 CAPLYTA net …

seekingalpha.com - August 12 at 10:29 AM. GW&K Investment Management LLC Purchases 302,685 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) marketbeat.com - August 11 at 7:34 PM. Barclays PLC Boosts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) marketbeat.com - August 8 at 6:11 AM.3 “Strong Buy” Stocks Showing Monster Growth. by Harold Vazquez. March 21, 2022Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($1.68) to ($0.80) per share. Intra-Cellular Therapies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More.ITCI The Nasdaq Global Select Market ... Common stock, $ 0.0001 par value: 175,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, ... Our Mission. Our mission is to deliver innovative treatments to improve the lives of individuals with neuropsychiatric, neurologic, and other disorders to reduce the burden on patients and their caregivers.ITCI Stock Overview. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system …

Intra-Cellular Therapies (ITCI) Stock Forecast, Price Targets and ...Intra-Cellular Therapies Inc. stock grades by Barron's. View ITCI fundamental and sentiment analysis powered by MarketGrader.

Intra-Cellular Therapies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ITCI updated stock price target summary.Find the latest on option chains for Intra-Cellular Therapies Inc. Common Stock (ITCI) at Nasdaq.com ... Financial analysts and individual investors can rely on the chain to gauge the stock's ...The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong …View the latest Intra-Cellular Therapies Inc. (ITCI) stock price, news, historical charts, analyst ratings and financial information from WSJ.Intra-Cellular Therapeutics ITCI incurred a loss of 45 cents per share in fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of 62 cents. The reported loss per share is also ...What is Intra-Cellular Therapies Inc (ITCI)'s stock price today? The current price of ITCI is $59.42. The 52 week high of ITCI is $67.05 and 52 week low is $42.01. When is next earnings date of Intra-Cellular Therapies Inc (ITCI)?Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shareholders might be concerned after seeing the share price drop 11% in the last month.But that doesn't change the fact that the returns over the last ...In addition, Intra-Cellular has granted the underwriters a 30-day option to purchase up to an additional 921,300 shares of common stock. In connection with the offering, shares of Intra-Cellular common stock will commence trading on the NASDAQ Global Select Market tomorrow morning under the ticker "ITCI."

NEW YORK March 26 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development. NEW YORK March 26 2019 (GLOBE NEWSWIRE) -- Intra ... home / stock / itci / itci news. RSS . ITCI ITCI Quote ITCI Short ITCI News ITCI Articles ITCI Message Board. March, 26 2019 …

ITCI stock rallied 2.2% Friday. Inspire Medical Systems ( INSP ) posted a weekly gain despite three losing days, gaining 3.8% Friday. INSP shares formed a handle and flirted with the 277.28 buy ...

Intra-Cellular Therapeutics ITCI incurred a loss of 45 cents per share in fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of 62 cents. The reported loss per share is also ...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Wall Street expects a year-over-year increase in earnings on higher revenues when Intra-Cellular Therapies (ITCI) reports results for the quarter...ITCI - Free Report) shares were up 2% on May 5, after the company reported better-than-expected first-quarter 2023 results on May 4. ITCI incurred a loss of 46 cents per share in the reported ...Nov 24, 2023 · Stock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Discover historical prices for ITCI stock on Yahoo Finance. View daily, weekly or monthly format back to when Intra-Cellular Therapies, Inc. stock was issued.Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ITCI stock stock is $78.5, which predicts an increase of 34.05%. The lowest target is $62 and the highest is $101. On average, analysts rate ITCI stock stock as a strong buy.February 22, 2023 at 10:00 AM · 5 min read. The market expects Intra-Cellular Therapies (ITCI) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the ...Get Intra-Cellular Therapies Inc (ITCI.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

Mar 6, 2023 · Read why ITCI stock is a Hold. Intra-Cellular Therapeutics develops small molecule drugs targeting the CNS for neuropsychiatric and neurological disorders. Read why ITCI stock is a Hold. Despite the negative momentum in the past three months at -12.40%, the 6 and 9-month momentum are positive at +19.58% and +14.86% respectively, contrasting slightly with the stock's minor decline ...Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report. ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report. Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report.Referenced Symbols. Shares of Intra-Cellular Therapies Inc. ITCI, +3.26% jumped about 15% in premarket trading on Tuesday after the company said its experimental treatment for major depressive ...Instagram:https://instagram. best stock research sitesinvestment simulatorsdeevx stockbest copy trading platforms On January 7, 2022, the Company completed a public offering of common stock in which the Company sold 10,952,381 shares of common stock at a public offering price of $ 42.00 per share for aggregate gross proceeds of $ 460.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were … europacific growth fund r6international reit The stock price for . Intra-Cellular Therapies (NASDAQ: ITCI) is $59.42 last updated November 24, 2023 at 6:00 PM UTC. Q Does Intra-Cellular Therapies (ITCI) pay a dividend? current i bonds rates Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...The average Intra Cellular Therapies stock price prediction forecasts a potential upside of 36.74% from the current ITCI share price of $57.19. What is ITCI's forecast return on assets (ROA) for 2023-2026?Nov 20, 2023 · Price Performance Review of ITCI. On Friday, Intra-Cellular Therapies Inc [NASDAQ:ITCI] saw its stock jump 3.94% to $57.19. On the same session, the stock had its day’s lowest price of $54.17, but rose to a high of $57.33. Over the last five days, the stock has gained 6.98%.